In Switch Label Studies, FDA Carefully Reads Data On Low-Literacy Consumers
This article was originally published in The Tan Sheet
Switch sponsors should include low-literacy subjects in label comprehension studies to address the “real risk” of taking an Rx product OTC, says a CDER Division of Nonprescription Drug Products social scientist. Self-selection studies similarly should include at-risk consumer populations.
You may also be interested in...
Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.
Final guidance on Rx-to-OTC self-selection studies makes space for investigation of novel switches under NSURE by recommending researchers ask complex questions that “involve a higher level of understanding” of multiple label elements at once.
Final guidance for label comprehension studies replaces several draconian draft recommendations with more flexible "common sense" measures, but drug sponsors may need to conduct significantly larger, more expensive studies and meet more extensively with the agency, experts say